Cardiovascular Imaging and Theranostics in Cardiovascular Pharmacotherapy

Login or register to view PDF.

Imaging plays a pivotal role in the diagnostic and prognostic assessment of cardiovascular diseases. During the past two decades, there has been an expansion of the available imaging techniques, some of which are now part of routine clinical practice. Cardiovascular imaging of atherosclerosis is a useful instrument, and it can corroborate and expand pathophysiological evidence on cardiovascular disease, providing proof of concept for medical therapy and can predict its responsiveness, and it may be able to be used as surrogate endpoints for clinical trials. Theranostics is an emerging therapy that combines imaging and therapeutic functions, using imaging-based therapeutic delivery systems. Theranostics could partially overcome current imaging limitations and translate experimental evidence and large-scale trials assessing clinical endpoints, rationalising cardiovascular drug development and paving the way to personalised medicine. The medical community cannot overlook the use of cardiovascular imaging as a complementary and supportive adjunct to trials investigating clinical endpoints, which remain the mainstay for investigating the efficacy and safety of cardiovascular pharmacotherapy

MC has received research grants from the Swiss Heart Foundation unrelated to this topic. AG has received research grants from the Swiss Heart Foundation related to this topic. AF has no conflicts of interest to declare
Mattia Cattaneo, Cardiovascular Research Unit, Ospedale Regionale di Bellinzona e Valli, 6500 Bellinzona, Switzerland. E:
Received date
20 January 2019
Accepted date
28 January 2019
European Cardiology Review 2019;14(1):62–4
Open access
This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.

Imaging has played an instrumental role in the diagnostic and prognostic assessment of cardiovascular diseases. Arterial Doppler ultrasound, echocardiography, myocardial perfusion imaging tests and angiography are now part of everyday clinical practice and represent a cornerstone of atherosclerosis management.1 During the past two decades, there has been an expansion of the available imaging techniques, some of which give us greater understanding of atherosclerosis in both coronary and peripheral arteries. This article summarises the current and potential role and limitations of emerging imaging techniques in demonstrating mechanisms of atherosclerosis, focusing on the potential translational role of theranostics in cardiovascular drug design and personalised cardiovascular medicine.

Cardiovascular Imaging: A Growing Field

Acute cardiovascular events result from the multifaceted relationship between a patient’s atherosclerotic risk factors and local factors, such as the location, burden, metabolic and functional characteristics of atherosclerotic disease that go beyond simple lumen stenosis.2–4 Consequently, scientific interest has moved from the degree of the lumen stenosis to investigating vessel wall structure, haemodynamic features, and the molecular and cellular mechanisms underlying atherogenesis, progression and thrombosis. Optical coherence tomography (OCT); coronary intravascular ultrasound (IVUS); coronary CT angiography; high-resolution MRI; nuclear imaging such as PET and spectroscopy; molecular imaging by contrast media for OCT, ultrasound and MRI; and fusion imaging have the potential to broaden our structural, functional and biological understanding of plaque.5–9 Likewise, computational flow dynamics allows the appraisal of the biomechanical factors of atherosclerosis.10

These invasive and non-invasive techniques are shedding light on the identification of vulnerable plaque, which is one of the greatest challenges in cardiovascular medicine. Cardiovascular imaging has provided the proof of concept for medical therapy such as the stabilisation and regression of atherosclerosis with statins and, more recently, by the use of the PKSK9 inhibitors.11,12 Notably, cardiovascular imaging may be able to anticipate the beneficial effect of pharmacological agents on clinical endpoints and patients’ potential responsiveness to these agents.13 However, this may not provide sufficient evidence to change clinical practice, since it should be supported by large-scale trials possibly assessing both imaging and clinical endpoints. This would allow a rationalisation of cardiovascular drug development.

Limitations and Perspectives

Currently, there is no consensus on the specific roles of different imaging modalities or the best targets for imaging in the clinical setting. Despite the expectations for being able to phenotype atherosclerosis by distinct features, imaging cannot predict clinical outcome with sufficient accuracy as a standalone technique. This is exemplified by a randomised clinical trial of dalcetrapid, which failed to demonstrate a reduction in major cardiovascular events, despite initial encouraging results in MRI and PET/CT primary endpoints.14,15

An explanation may reside in the inability of the imaging’s surrogate endpoints to detect either the ancillary and/or systemic mechanisms of action of the drug being investigated or any genetic differences among patients that may affect the clinical outcome. The concept of the risk continuum in atherosclerosis is progressively taking over from the categorical classification of vulnerable plaque, and the vulnerable plaque (rupture- and erosion-prone) concept is being integrated with the vulnerable patient concept.16–19 Naghavi et al. have suggested a cumulative vulnerability index to assess total vulnerability burden and strengthening traditional risk assessment strategies with imaging and biological findings. This should include the consideration of local, systemic and haematic features and myocardial vulnerability.16 The scientific community must also consider the setbacks that hinder the translatability of the existing imaging techniques, particularly for radiation, contrast media exposure and high costs.20


Considering the complexity, rationalising cardiovascular drug development and moving towards personalised, preventive and therapeutic medicine should be a mainstay of future research. Theranostics could be used to help bridge the gap between experimental evidence and large-scale trials.

Theranostics combines imaging and therapeutic functions by using imaging-based therapeutic delivery systems. Studies have employed nanoparticles for contrast agent-assisted diagnostic imaging, therapeutic delivery and subsequent evaluation of therapeutic efficacy. Theranostics is a result of advances in multiple natural and material sciences, particularly nanotechnology. Primarily used in oncology, it has been gradually applied to early and late atherosclerotic lesions with encouraging results.21 In theranostics, drug delivery and subsequent action in a region of interest is controlled by an external energy field – mostly ultrasound, light, or a magnetic field – in an attempt to minimise systemic and local effects.22

Ultrasound’s intrinsic technical characteristics, including real-time imaging to avoid radiation, allowed its early implementation in theranostic. The Combined Lysis of Thrombus in Brain Ischemia using Transcranial Ultrasound and Systemic tPA (CLOTBUST) trial and a later meta-analysis demonstrated the efficacy of ultrasound-enhanced fibrinolysis.23,24 However, this was not supported by a recent multicentre randomised controlled trial, showing no benefit in sonothrombolysis delivered within 3 hours of symptom onset over classical thrombolysis by alteplase.25 Contrast-enhanced ultrasound-targeted microbubbles have been used to promote angiogenesis in a model of critical limb ischaemia, to attenuated arterial neointimal formation and reduce microvascular dysfunction after acute MI in a large animal model.26–29

Based on a similar principle, MRI has been used for site-specific vascular intervention. A magnetic field attracts and activates metallic nanoparticles with a protective coating to detect and inhibit inflammatory processes in atherosclerosis.30,31 In another study, gold nanorods were synthesised to diagnose and attenuate macrophage activity and release by delivering photodynamic therapy.32,33

Similarly, paramagnetic nanoparticles have delivered anti-proliferative drugs and micro-RNA to inhibit either proliferation of smooth muscle cells or angiogenesis.34,35 In the past 5 years, a variety of new nanoparticles targeting lipids, inflammation signalling, vascular growth factors, endothelial function, oxidative stress, platelets function and apoptosis signalling have been delivered in pre-clinical studies using MRI, nuclear imaging and novel technical advances such as photoacoustic imaging.36,37

The development of imaging systems specifically designed for theranostic use will improve its potential. However, unsolved issues related to potential harmful exposures and costs need to be addressed before application of theranostics in extended human research and clinical practice could be feasible.


Cardiovascular imaging of atherosclerosis is a useful instrument, which corroborates and expands pathophysiological evidence on cardiovascular disease, and provides proof of concepts for medical therapy. It might also be used to anticipate the beneficial effect on clinical endpoints and the responsiveness to medical therapy and can represent surrogate endpoints in clinical trials. Theranostics could further translate experimental evidence and large-scale trials assessing clinical endpoints, rationalising cardiovascular drug development and paving the way to more personalised medicine.

  1. Tonino PA, De Bruyne B, Pijls NH, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med 2009;360:213–24.; PMID: 19144937.
  2. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 2012;32:2045–51.; PMID: 22895665.
  3. Arbab-Zadeh A, Fuster V. The myth of the “vulnerable plaque”: transitioning from a focus on individual lesions to atherosclerotic disease burden for coronary artery disease risk assessment. J Am Coll Cardiol 2015;65:846–55.; PMID: 25601032.
  4. Stone GW, Maehara A, Lansky AJ, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med 2011;364:226–35.; PMID: 21247313.
  5. Ali ZA, Karimi Galougahi K, Maehara A, et al. Intracoronary optical coherence tomography 2018: current status and future directions. JACC Cardiovasc Interv 2017;10:2473–87.; PMID: 29268880.
  6. Matthews SD, Frishman WH. A review of the clinical utility of intravascular ultrasound and optical coherence tomography in the assessment and treatment of coronary artery disease. Cardiol Rev 2017;25:68–76.; PMID: 28099219.
  7. Foy AJ, Dhruva SS, Peterson B, et al. Coronary computed tomography angiography vs functional stress testing for patients with suspected coronary artery disease: a systematic review and meta-analysis. JAMA Intern Med 2017;177:1623–31.; PMID: 28973101.
  8. den Hartog AG, Bovens SM, Koning W, et al. Current status of clinical magnetic resonance imaging for plaque characterisation in patients with carotid artery stenosis. Eur J Vasc Endovasc Surg 2013;45:7–21.; PMID: 23200607.
  9. Osborn EA, Jaffer FA. The advancing clinical impact of molecular imaging in CVD. JACC Cardiovasc Imaging 2013;6:1327–41.; PMID: 24332285.
  10. Kwak BR, Back M, Bochaton-Piallat ML, et al. Biomechanical factors in atherosclerosis: mechanisms and clinical implicationsdagger. Eur Heart J 2014;35:3013–20.; PMID: 25230814.
  11. Girotra S, Murarka S, Migrino RQ. Plaque regression and improved clinical outcomes following statin treatment in atherosclerosis. Panminerva Med 2012;54:71–81. PMID: 22525562.
  12. Nicholls SJ, Puri R, Anderson T, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA 2016;316:2373–84.; PMID: 27846344.
  13. van Thienen JV, Fledderus JO, Dekker RJ, et al. Shear stress sustains atheroprotective endothelial KLF2 expression more potently than statins through mRNA stabilization. Cardiovasc Res 2006;72:231–40.; PMID: 16945356.
  14. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012;367:2089–99.; PMID: 23126252.
  15. Fayad ZA, Mani V, Woodward M, et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet 2011;378:1547–59.; PMID: 21908036.
  16. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation 2003;108:1772–8.; PMID: 14557340.
  17. Baber U, Mehran R, Sartori S, et al. Prevalence, impact, and predictive value of detecting subclinical coronary and carotid atherosclerosis in asymptomatic adults: the BioImage study. J Am Coll Cardiol 2015;65:1065–74.; PMID: 25790876.
  18. Libby P, Pasterkamp G. Requiem for the ‘vulnerable plaque’. Eur Heart J 2015;36:2984–7.; PMID: 26206212.
  19. Arbab-Zadeh A, Fuster V. The risk continuum of atherosclerosis and its implications for defining CHD by coronary angiography. J Am Coll Cardiol 2016;68:2467–78.; PMID: 27908353.
  20. Gallino A, Stuber M, Crea F, et al. “In vivo” imaging of atherosclerosis. Atherosclerosis 2012;224:25–36.; PMID: 22682779.
  21. Schinkel AF, Kaspar M, Staub D. Contrast-enhanced ultrasound: clinical applications in patients with atherosclerosis. Int J Cardiovasc Imaging 2016;32:35–48.; PMID: 26206524.
  22. Eraso LH, Reilly MP, Sehgal C, et al. Emerging diagnostic and therapeutic molecular imaging applications in vascular disease. Vasc Med 2011;16:145–56.; PMID: 21310769.
  23. Tsivgoulis G, Eggers J, Ribo M, et al. Safety and efficacy of ultrasound-enhanced thrombolysis: a comprehensive review and meta-analysis of randomized and nonrandomized studies. Stroke 2010;41:280–7.; PMID: 20044531.
  24. Barreto AD, Alexandrov AV, Shen L, et al. CLOTBUST-Hands Free: pilot safety study of a novel operator-independent ultrasound device in patients with acute ischemic stroke. Stroke 2013;44:3376–81.; PMID: 24159060.
  25. Alexandrov AV, Köhrmann M, Soinne L, et al. Safety and efficacy of sonothrombolysis for acute ischaemic stroke: a multicentre, double-blind, phase 3, randomised controlled trial. CLOTBUST-ER Trial. Lancet Neurol 2019;18:338–47.; PMID: 30878103.
  26. Leong-Poi H, Kuliszewski MA, Lekas M, et al. Therapeutic arteriogenesis by ultrasound-mediated VEGF165 plasmid gene delivery to chronically ischemic skeletal muscle. Circ Res 2007;101:295–303.; PMID: 17585071.
  27. Kobulnik J, Kuliszewski MA, Stewart DJ, et al. Comparison of gene delivery techniques for therapeutic angiogenesis ultrasound-mediated destruction of carrier microbubbles versus direct intramuscular injection. J Am Coll Cardiol 2009;54:1735–42.; PMID: 19850216.
  28. Suzuki J, Ogawa M, Takayama K, et al. Ultrasound-microbubble-mediated intercellular adhesion molecule-1 small interfering ribonucleic acid transfection attenuates neointimal formation after arterial injury in mice. J Am Coll Cardiol 2010;55:904–13.; PMID: 20185042.
  29. Xie F, Lof J, Matsunaga T, et al. Diagnostic ultrasound combined with glycoprotein IIb/IIIa-targeted microbubbles improves microvascular recovery after acute coronary thrombotic occlusions. Circulation 2009;119:1378–85.; PMID: 19255341.
  30. Sun C, Lee JS, Zhang M. Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev 2008;60:1252–65.; PMID: 18558452.
  31. Palekar RU, Jallouk AP, Lanza GM, et al. Molecular imaging of atherosclerosis with nanoparticle-based fluorinated MRI contrast agents. Nanomedicine (Lond) 2015;10:1817–32.; PMID: 26080701.
  32. Shon SM, Choi Y, Kim JY, et al. Photodynamic therapy using a protease-mediated theranostic agent reduces cathepsin-B activity in mouse atheromata in vivo. Arterioscler Thromb Vasc Biol 2013;33:1360–5.; PMID: 23539220.
  33. Qin J, Peng Z, Li B, et al. Gold nanorods as a theranostic platform for in vitro and in vivo imaging and photothermal therapy of inflammatory macrophages. Nanoscale 2015;7:13991–4001.; PMID: 26228112.
  34. Lanza GM, Yu X, Winter PM, et al. Targeted antiproliferative drug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent: implications for rational therapy of restenosis. Circulation 2002;106:2842–7.; PMID: 12451012.
  35. Winter PM, Neubauer AM, Caruthers SD, et al. Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler Thromb Vasc Biol 2006;26:2103–9.; PMID: 16825592.
  36. Bejarano J, Navarro-Marquez M, Morales-Zavala F, et al. Nanoparticles for diagnosis and therapy of atherosclerosis and myocardial infarction: evolution toward prospective theranostic approaches. Theranostics 2018;8:4710–32.; PMID: 30279733.
  37. Jung E, Kang C, Lee J, et al. Molecularly engineered theranostic nanoparticles for thrombosed vessels: h2o2-activatable contrast-enhanced photoacoustic imaging and antithrombotic therapy. ACS Nano 2018;12:392–401.; PMID: 29257881.